{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:51:35Z","timestamp":1785887495673,"version":"3.56.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008271","name":"LEO Pharma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008271","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jtha.2026.04.028","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T23:36:05Z","timestamp":1778283365000},"page":"2923-2936","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Development of models for predicting the 7-month risk of venous thromboembolism and clinically relevant bleeding in ambulatory patients with cancer: analysis from the apixaban for the prevention of venous thromboembolism in high-risk ambulatory cancer patients trial"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9154-4123","authenticated-orcid":false,"given":"Danielle Carole","family":"Roy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Fei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjeeta","family":"Mallick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dylan","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Carrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Hawken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2026.04.028_bib1","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.2020007338","article-title":"Venous thromboembolism in cancer patients: a population-based cohort study","volume":"137","author":"Mulder","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.04.028_bib2","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1111\/jth.14614","article-title":"Risk factors for cancer-associated venous thromboembolism: The venous thromboembolism prevention in the ambulatory cancer clinic (VTE-PACC) study","volume":"17","author":"Douce","year":"2019","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.04.028_bib3","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/cncr.27772","article-title":"Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States","volume":"119","author":"Khorana","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.jtha.2026.04.028_bib4","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3390\/cancers12010075","article-title":"A case-control analysis of the impact of venous thromboembolic disease on quality of life of patients with cancer: quality of life in cancer (Qca) study","volume":"12","author":"Marin-Barrera","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.jtha.2026.04.028_bib5","doi-asserted-by":"crossref","first-page":"4072","DOI":"10.1182\/bloodadvances.2022009577","article-title":"Survival after cancer-related venous thrombosis: the Scandinavian thrombosis and cancer study","volume":"7","author":"Crobach","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2026.04.028_bib6","article-title":"Update on guidelines for the prevention of cancer-associated thrombosis","volume":"20","author":"Elshoury","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.jtha.2026.04.028_bib7","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1111\/jth.14564","article-title":"The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: guidance from the SSC of the ISTH","volume":"17","author":"Wang","year":"2019","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.04.028_bib8","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.23.00294","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update","volume":"41","author":"Key","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtha.2026.04.028_bib9","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.04.028_bib10","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.04.028_bib11","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtha.2026.04.028_bib12","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.3324\/haematol.2018.209114","article-title":"The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis","volume":"104","author":"Mulder","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2026.04.028_bib13","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1002\/rth2.12431","article-title":"Preventing venous thromboembolism in oncology practice: Use of risk assessment and anticoagulation prophylaxis","volume":"4","author":"Martin","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.04.028_bib14","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.3390\/diagnostics14111159","article-title":"Venous thromboembolism prophylaxis in gynecologic oncology: a MITO-MaNGO survey","volume":"14","author":"Mongelli","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"10.1016\/j.jtha.2026.04.028_bib15","doi-asserted-by":"crossref","first-page":"5377","DOI":"10.1182\/blood-2010-02-270116","article-title":"Prediction of venous thromboembolism in cancer patients","volume":"116","author":"Ay","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2026.04.028_bib16","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11739-012-0784-y","article-title":"A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score","volume":"7","author":"Verso","year":"2012","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.jtha.2026.04.028_bib17","first-page":"2084","article-title":"[Primary pharmacological prevention of thromboembolic events in ambulatory patients with advanced pancreatic cancer treated with chemotherapy?]","volume":"138","author":"Pelzer","year":"2013","journal-title":"Dtsch Med Wochenschr"},{"key":"10.1016\/j.jtha.2026.04.028_bib18","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1634\/theoncologist.2016-0414","article-title":"A predictive score for thrombosis associated with breast, colorectal, lung, or ovarian cancer: the prospective COMPASS\u2013cancer-associated thrombosis study","volume":"22","author":"Gerotziafas","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.jtha.2026.04.028_bib19","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1016\/S2352-3026(18)30063-2","article-title":"A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts","volume":"5","author":"Pabinger","year":"2018","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2026.04.028_bib20","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/s41416-018-0027-8","article-title":"Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer","volume":"118","author":"Mu\u00f1oz Mart\u00edn","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtha.2026.04.028_bib21","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1200\/JCO.22.00255","article-title":"A clinical-genetic risk score for predicting cancer-associated venous thromboembolism: a development and validation study involving two independent prospective cohorts","volume":"41","author":"Mu\u00f1oz","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtha.2026.04.028_bib22","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.3324\/haematol.2017.169060","article-title":"Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study","volume":"102","author":"van Es","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2026.04.028_bib23","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s11239-019-01845-6","article-title":"Long-term performance of risk scores for venous thromboembolism in ambulatory cancer patients","volume":"48","author":"Di Nisio","year":"2019","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jtha.2026.04.028_bib24","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s12032-018-1120-9","article-title":"Evaluation of risk factors and assessment models for predicting venous thromboembolism in lung cancer patients","volume":"35","author":"Rupa-Matysek","year":"2018","journal-title":"Med Oncol"},{"key":"10.1016\/j.jtha.2026.04.028_bib25","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1111\/jth.15503","article-title":"Evaluation of the Khorana, PROTECHT, and 5-SNP scores for prediction of venous thromboembolism in patients with cancer","volume":"19","author":"Guman","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.04.028_bib26","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.thromres.2023.11.006","article-title":"Comparison of risk prediction scores for cancer-associated thrombosis in ambulatory cancer patients not receiving thromboprophylaxis: a prospective cohort study in a South-East Asian population","volume":"232","author":"Thipbumrung","year":"2023","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2026.04.028_bib27","doi-asserted-by":"crossref","first-page":"e1083","DOI":"10.1634\/theoncologist.2019-0482","article-title":"External validation of a venous thromboembolic risk score for cancer outpatients with solid tumors: the COMPASS-CAT venous thromboembolism risk assessment model","volume":"25","author":"Spyropoulos","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.jtha.2026.04.028_bib28","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/j.jtha.2023.03.037","article-title":"Utility of the Khorana and the new-Vienna CATS prediction scores in cancer patients of the HYPERCAN cohort","volume":"21","author":"Verzeroli","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.04.028_bib29","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1200\/JCO.22.01542","article-title":"Derivation and validation of a clinical risk assessment model for cancer-associated thrombosis in two unique US health care systems","volume":"41","author":"Li","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtha.2026.04.028_bib30","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1002\/ajh.26928","article-title":"External validation of a novel electronic risk score for cancer-associated thrombosis in a comprehensive cancer center","volume":"98","author":"Li","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2026.04.028_bib31","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.jtha.2024.11.001","article-title":"Machine learning models for risk prediction of cancer-associated thrombosis: a systematic review and meta-analysis","volume":"23","author":"Chen","year":"2025","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.04.028_bib32","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2023-002273","article-title":"External validation and updating of prediction models of bleeding risk in patients with cancer receiving anticoagulants","volume":"10","author":"Trinks-Roerdink","year":"2023","journal-title":"Open Heart"},{"key":"10.1016\/j.jtha.2026.04.028_bib33","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1183\/13993003.00280-2016","article-title":"Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment","volume":"48","author":"Klok","year":"2016","journal-title":"Eur Respir"},{"key":"10.1016\/j.jtha.2026.04.028_bib34","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.jtha.2026.04.028_bib35","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jacc.2011.03.031","article-title":"A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (anticoagulation and risk factors in atrial fibrillation) Study","volume":"58","author":"Fang","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jtha.2026.04.028_bib36","first-page":"3258","article-title":"The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation","volume":"36","author":"O\u2019Brien","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jtha.2026.04.028_bib37","article-title":"Tailoring anticoagulant treatment of patients with atrial fibrillation using a novel bleeding risk score","author":"Chu","year":"2020","journal-title":"Heart"},{"key":"10.1016\/j.jtha.2026.04.028_bib38","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1055\/s-0041-1735251","article-title":"Estimating bleeding risk in patients with cancer-associated thrombosis: evaluation of existing risk scores and development of a new risk score","volume":"122","author":"de Winter","year":"2022","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.04.028_bib39","article-title":"1856P Prediction of clinically significant bleeding in anticoagulated patients for cancer-associated venous thromboembolism: validation of B-CAT score in a cohort from the TESEO study","volume":"35","author":"Robles","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtha.2026.04.028_bib40","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1016\/j.jtha.2023.07.017","article-title":"Thrombophilia gene mutations predict venous thromboembolism in ambulatory cancer patients receiving chemotherapy","volume":"21","author":"Roy","year":"2023","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.04.028_bib41","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/rth2.12342","article-title":"A risk score for prediction of venous thromboembolism in gynecologic cancer: the Thrombogyn score","volume":"4","author":"Norris","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.04.028_bib42","doi-asserted-by":"crossref","first-page":"313","DOI":"10.4103\/joah.joah_106_24","article-title":"Enhancing venous thromboembolism risk prediction through novel biomarkers and inflammatory indicators","volume":"15","author":"Al-Maaroof","year":"2024","journal-title":"J Appl Hematol"},{"key":"10.1016\/j.jtha.2026.04.028_bib43","doi-asserted-by":"crossref","DOI":"10.2196\/jmir.5870","article-title":"Guidelines for developing and reporting machine learning predictive models in biomedical research: a multidisciplinary view","volume":"18","author":"Luo","year":"2016","journal-title":"J Med Internet Res"},{"key":"10.1016\/j.jtha.2026.04.028_bib44","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-078378","article-title":"TRIPOD+AI statement: updated guidance for reporting clinical prediction models that use regression or machine learning methods","volume":"385","author":"Collins","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.jtha.2026.04.028_bib45","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1111\/jth.13140","article-title":"Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH","volume":"13","author":"Kaatz","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.04.028_bib46","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.04.028_bib47","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.annonc.2022.12.014","article-title":"Venous thromboembolism in cancer patients: ESMO clinical practice guideline","volume":"34","author":"Falanga","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtha.2026.04.028_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v033.i01","article-title":"Regularization Paths for Generalized Linear Models via Coordinate Descent","volume":"33","author":"Friedman","year":"2010","journal-title":"J Stat Softw"},{"key":"10.1016\/j.jtha.2026.04.028_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v106.i01","article-title":"Elastic net regularization paths for all generalized linear models","volume":"106","author":"Tay","year":"2023","journal-title":"J Stat Softw"},{"key":"10.1016\/j.jtha.2026.04.028_bib50","author":"Chen"},{"key":"10.1016\/j.jtha.2026.04.028_bib51","author":"Canty"},{"key":"10.1016\/j.jtha.2026.04.028_bib52","series-title":"Bootstrap Methods and Their Application","author":"Davison","year":"1997"},{"key":"10.1016\/j.jtha.2026.04.028_bib53","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12634","article-title":"Evaluation of the Khorana score for prediction of venous thromboembolism in patients with multiple myeloma","volume":"6","author":"Sanfilippo","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2026.04.028_bib54","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1177\/00033197231213197","article-title":"Development and validation of a modified Khorana score for predicting venous thromboembolism in newly diagnosed stage IV lung cancer","volume":"76","author":"Qin","year":"2025","journal-title":"Angiology"},{"key":"10.1016\/j.jtha.2026.04.028_bib55","article-title":"The value of COMPASS-CAT risk assessment model in predicting venous thromboembolism in hospitalized patients with breast cancer, lung cancer, colorectal cancer and ovarian cancer","author":"Wei","year":"2024","journal-title":"Res Sq"},{"key":"10.1016\/j.jtha.2026.04.028_bib56","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.3332\/ecancer.2022.1470","article-title":"Using the Khorana risk score to predict venous thromboembolism and overall survival in a cohort of Hispanic patients with solid malignancies","volume":"16","author":"Ramos-Esquivel","year":"2022","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.jtha.2026.04.028_bib57","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.jacasi.2021.07.006","article-title":"Validation of the Khorana venous thromboembolism risk score in Japanese cancer patients","volume":"1","author":"Akasaka-Kihara","year":"2021","journal-title":"JACC Asia"},{"key":"10.1016\/j.jtha.2026.04.028_bib58","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1634\/theoncologist.2016-0246","article-title":"Preventing venous thromboembolism in ambulatory cancer patients: the ONKOTEV study","volume":"22","author":"Cella","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.jtha.2026.04.028_bib59","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.thromres.2020.09.031","article-title":"Increased D-dimer predicts the risk of cancer-associated recurrent venous thromboembolism and venous thromboembolism: a systematic review and meta-analysis","volume":"196","author":"Yang","year":"2020","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2026.04.028_bib60","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.thromres.2018.04.009","article-title":"Extracellular vesicles exposing tissue factor for the prediction of venous thromboembolism in patients with cancer: a prospective cohort study","volume":"166","author":"van Es","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2026.04.028_bib61","doi-asserted-by":"crossref","first-page":"e329","DOI":"10.5858\/arpa.2024-0276-OA","article-title":"Peripheral blood plasminogen activator inhibitor 1 and tissue-type plasminogen activator-inhibitor complex levels for the diagnosis and prediction value of venous thromboembolism in malignant tumors","volume":"149","author":"Yu","year":"2025","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.jtha.2026.04.028_bib62","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1182\/bloodadvances.2020003149","article-title":"Plasminogen activator inhibitor 1 and venous thrombosis in pancreatic cancer","volume":"5","author":"Hisada","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2026.04.028_bib63","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1002\/ajh.25494","article-title":"Bleeding incidence and risk factors among cancer patients treated with anticoagulation","volume":"94","author":"Angelini","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2026.04.028_bib64","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.amjcard.2021.11.053","article-title":"Incidence and predictors of bleeding in patients with cancer and atrial fibrillation","volume":"167","author":"Raposeiras Roub\u00edn","year":"2022","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jtha.2026.04.028_bib65","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1055\/s-0039-3402429","article-title":"The role of platelets in cancer-related bleeding risk: a systematic review","volume":"46","author":"Larsen","year":"2020","journal-title":"Semin Thromb Hemost"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626002795?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783626002795?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:23:57Z","timestamp":1785885837000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783626002795"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":65,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1538783626002795"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2026.04.028","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of models for predicting the 7-month risk of venous thromboembolism and clinically relevant bleeding in ambulatory patients with cancer: analysis from the apixaban for the prevention of venous thromboembolism in high-risk ambulatory cancer patients trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2026.04.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}